Cortical circuit dysfunction and cognitive deficits in schizophrenia - implications for preemptive interventions

1 Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial Schizophrenia Research, May 6, 2013

2 The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort Schizophrenia Research, May 17, 2013

3 Practical management of schizophrenia: The role of long-acting Antipsychotics International Clinical Psychopharmacology, May 20, 2013

4 Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia International Clinical Psychopharmacology, April 25, 2013

5 Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia Psychiatry Research, May 1, 2013    Review Article

6 Benzodiazepines for psychosis-induced aggression or agitation Cochrane Reviews, May 8, 2013

7 Challenges in the Treatment of Major Depressive Disorder With Psychotic Features Schizophrenia Bulletin, April 24, 2013    Review Article

8 Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials European Neuropsychopharmacology, April 26, 2013    Evidence Based Medicine    Review Article

9 Incidence and prevalence of treated epilepsy among poor health and low-income Americans Neurology, April 29, 2013

10 A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities Schizophrenia Research, April 26, 2013    Evidence Based Medicine    Review Article